David Lebowitz
Stock Analyst at Citigroup
(4.29)
# 370
Out of 5,063 analysts
119
Total ratings
59.77%
Success rate
13.06%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $74.35 | +12.98% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $64.55 | +30.13% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $25.51 | +88.16% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $16.24 | +23.15% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $207.57 | +39.71% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $101.87 | +1.11% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $33.32 | +14.05% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $35.54 | -38.10% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $67.35 | -0.52% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $42.11 | +32.99% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $8.10 | +23.46% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.55 | -3.23% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $77.91 | -42.24% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $70.59 | -3.67% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $560.90 | -31.90% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $53.66 | +78.90% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.71 | +78.97% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $445.41 | -63.18% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $28.03 | +39.14% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $17.04 | +23.24% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $5.72 | +6,985.37% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.21 | +336.14% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $74.35
Upside: +12.98%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $64.55
Upside: +30.13%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $25.51
Upside: +88.16%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $16.24
Upside: +23.15%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $207.57
Upside: +39.71%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $101.87
Upside: +1.11%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $33.32
Upside: +14.05%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $35.54
Upside: -38.10%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $67.35
Upside: -0.52%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $42.11
Upside: +32.99%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $8.10
Upside: +23.46%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.55
Upside: -3.23%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $77.91
Upside: -42.24%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $70.59
Upside: -3.67%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $560.90
Upside: -31.90%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $53.66
Upside: +78.90%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.71
Upside: +78.97%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $445.41
Upside: -63.18%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $28.03
Upside: +39.14%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $17.04
Upside: +23.24%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $5.72
Upside: +6,985.37%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.21
Upside: +336.14%